Abstract
The emergence of drug-eluting stents (DES) has led to a significant reduction in in-stent restenosis (ISR) rates, one of the major limitations of bare-metal stents (BMS) (1). Consequently DES have become the preferred strategy in contemporary percutaneous coronary intervention (PCI) (2). Although rates of ISR are at historical low levels, optimal management remains an important issue as PCI for ISR is associated with a worse prognosis than de novo coronary interventions (3).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
